NEW YORK – Ensem Therapeutics on Thursday closed a $67 million Series A financing round, led by GGV Capital.
Other investors in the Series A2 portion of the funding round included Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, and CBC Group. Ensem was incubated by the healthcare investment fund CBC Group.
The Boston-based company will use the funding to advance its precision medicine pipeline and its Kinetic Ensemble artificial intelligence-driven drug discovery platform. The company initially aims to use the platform to develop small molecule precision oncology drugs and may expand into genetic disorders and other disease areas in the future.
"Our team has developed Kinetic Ensemble, a novel multi-tiered platform integrating molecular simulation, AI deep learning, and advanced experimental validation by state-of-the-art macromolecular dynamic techniques," Ensem President Shengfang Jin said in a statement. "We expect many of these programs will reveal non-obvious binding sites as drug targets and create novel classes of small molecule therapeutics."
The Kinetic Ensemble platform homes in on the conformational states of proteins and RNA, or the spatial arrangements and movement of atoms in a molecule. The platform is able to map these arrangements to identify new drug targets. The conformational states can also underpin oncogenic, regulatory, and drug-resistance mechanisms, according to Ensem.